3839 CPBIO Holding Company Limited
CPBIO Holding Company (3839) news
CPBIO Holding Company Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 3839, recorded under Hong Kong. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest CPBIO Holding Company news
We have not published a story on CPBIO Holding Company yet. When there is news, it will appear here.
Questions about CPBIO Holding Company
What is the ticker symbol of CPBIO Holding Company?
CPBIO Holding Company Limited trades under the ticker 3839 on HKEX.
Where is CPBIO Holding Company listed?
CPBIO Holding Company Limited is listed on HKEX.
Which country or territory is CPBIO Holding Company listed under?
Our directory records CPBIO Holding Company Limited under Hong Kong.
What does CPBIO Holding Company do?
Our directory classifies CPBIO Holding Company Limited as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of CPBIO Holding Company?
The ISIN recorded for CPBIO Holding Company Limited is BMG2151A1036.
Does aibio.space cover CPBIO Holding Company?
aibio.space lists CPBIO Holding Company Limited among 2,820 public biotech companies and publishes its news here as stories appear.
Which companies are similar to CPBIO Holding Company?
Companies in our directory listed in the same country and business area as CPBIO Holding Company: Sirnaomics, Genscript Biotech, China NT Pharma Group Co., SinoMab Bioscience, China Resources Pharmaceutical Group, SSY Group.
Investor discussion: CPBIO Holding Company
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Share consolidation: Change of Company Name, Stock Short Name, Company Logo and Company Website. Source
- Financings
Share or debt issue: Re-election of Retiring Directors, Re-appointment of Auditor, General Mandates to Issue New Shares and Buy Back Shares, Proposed Change of Company Name and Notice of Annual General Meeting. Source
- Financings
Share or debt issue: Re-election of Retiring Directors, General Mandates to Issue New Shares and Buy Back Shares, Adoption of the 2025 Share Option Scheme and Termination of the 2015 Share Option Scheme and Notice of Annual General Meeting. Source
Press releases
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
Renewal of Continuing Connected Transactions and Notice of Special General Meeting
- HKEXnews
Letter to Non-Registered Shareholders and Reply Form - Notice of Publication of 2026 Interim Report
- HKEXnews
Letter to Registered Shareholders and Reply Form - Notice of Publication of 2026 Interim Report
- HKEXnews
- HKEXnews
Announcement of Interim Results for the Six Months Ended 30 June 2026
- HKEXnews
Profit Warning - Estimated Profit in Preliminary 2026 Interim Results
- HKEXnews
Change of Company Name, Stock Short Name, Company Logo and Company Website
- HKEXnews
Poll Results of the Annual General Meeting Held on 9 June 2026
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
Profit Warning - Estimated Profit in Preliminary 3M2026 Results
- HKEXnews
- HKEXnews
Stock chart
Listing details
- Company
- CPBIO Holding Company Limited
- Ticker
- 3839
- Listing
- HKEX
- Country or territory
- Hong Kong
- Business scope
- Biotechnology
- ISIN
- BMG2151A1036
- Last quote in directory
- 2026-10-20
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio